We are live on
!
Find out more
SB
Samsara BioCapital Portfolio holdings
AUM
$1.03B
1-Year Est. Return
214.94%
This Fund
S&P 500
This Quarter
Est. Return
-11.56%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$375M
AUM Growth
-$22.1M
(-5.6%)
Cap. Flow
+$63.9M
Cap. Flow
% of AUM
17.03%
Top 10 Holdings %
Top 10 Hldgs %
64.63%
Holding
62
New
5
Increased
7
Reduced
14
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$30.6M |
| 2 |
Nkarta
NKTX
|
+$10.9M |
| 3 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$9.68M |
| 4 |
HLVX
HilleVax
HLVX
|
+$9.06M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$8.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$3.17M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
+$1.81M |
| 3 |
Instil Bio
TIL
|
+$1.44M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$1.37M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$1.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.54% |
| 2 | Financials | 2.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KLRS
51
Kalaris Therapeutics
KLRS
$96.8M
| $321K | 0.09% |
3,580
| – | – |
|
|
KRON
52
DELISTED
Kronos Bio
KRON
| $284K | 0.08% |
78,131
| – | – |
|
53
KALA BIO
KALA
$14.5M
| $180K | 0.05% |
241
| – | – |
|
|
NGM
54
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $175K | 0.05% |
13,669
| – | – |
|
|
ATXS
55
DELISTED
Astria Therapeutics
ATXS
| $75K | 0.02% |
25,000
| – | – |
|
|
NUVB.WS
56
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $37K | 0.01% |
+133,333
| New | +$85.8K |
|
57
Surrozen Inc Warrant
SRZNW
$8.86K
| $19K | 0.01% |
+99,999
| New | +$22.5K |
|
|
AMRN
58
Amarin Corp
AMRN
$303M
| – | – |
-1,250
| Closed | -$82K |
|
59
BioNTech
BNTX
$23.5B
| – | – |
-4,031
| Closed | -$688K |
|
60
Rocket Pharmaceuticals
RCKT
$394M
| – | – |
-40,550
| Closed | -$643K |
|
61
VistaGen Therapeutics
VTGN
$12.8M
| – | – |
-16,288
| Closed | -$606K |
|
|
ODT
62
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| – | – |
-700,421
| Closed | -$925K |
|
Similar funds
MA
WHCM
JSC
IAS
CM
CFFNO
MSA
TBA
Samsara BioCapital's Q2 2022 Portfolio in Review
As of Q2 2022, Samsara BioCapital held 62 positions worth $375M, down 5.6% from $397M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Samsara BioCapital deployed $63.9M of net new capital in Q2 2022, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was LYRA THERAPEUTICS INC: 35,545 shares worth $10M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $3.17M trimmed.
- Samsara BioCapital's largest Q2 2022 buy was LYRA THERAPEUTICS INC: 35,545 shares worth $10M.
- Samsara BioCapital added most to Scholar Rock in Q2 2022, an estimated $30.6M increase.
- Samsara BioCapital's biggest Q2 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $3.17M.
- Samsara BioCapital fully exited Odonate Therapeutics, Inc. Common Stock in Q2 2022, selling an estimated $925K.
- Samsara BioCapital's ten largest holdings make up 65% of its $375M portfolio in Q2 2022.
- Samsara BioCapital opened 5 new positions and closed 5 in Q2 2022.
- Samsara BioCapital's portfolio value fell 5.6% quarter-over-quarter to $375M.
Based on Samsara BioCapital's 13F filing for Q2 2022, filed 15 Aug 2022.